アルツハイマー病診断の市場規模、シェア、動向分析レポート：診断技術別、タイプ別、最終用途別、地域別、セグメント別予測、2024年～2030年

アルツハイマー病診断市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、アルツハイマー病診断の世界市場規模は、2024年から2030年にかけて11.4%のCAGRを記録し、2030年までに159億2,000万米ドルに達すると予測されています。

この市場は、アルツハイマー病（AD）の有病率の上昇、疾患診断におけるバイオマーカーの使用の増加、個別化製品の採用の増加、医療用画像診断における技術進歩の増加が、アルツハイマー病診断の需要を促進すると予想される要因の一部です。政府投資と研究開発研究の増加は、成長をさらに促進しています。

認知症で最も一般的なアルツハイマー病などの慢性疾患を抱える世界の高齢化も、アルツハイマー病診断市場を牽引する大きな要因です。WHOによると、アルツハイマー病は認知症全体の60～70%を引き起こし、最も一般的な認知症です。Alzheimer's Associationの報告によると、2023年には65歳以上のアメリカ人のうち670万人がアルツハイマー病を患っていると推定されています。この数は2060年までに3倍近い1,380万人になると予測されており、2022年の米国におけるアルツハイマー病患者のヘルスケアコストは約3,210億米ドルに上ると予測されています。

新興国市場の動向は、より正確で非侵襲的な診断ツールの開拓へとシフトしています。最近の技術の動向により、脳脊髄液や血液サンプルから検出可能なアミロイド・ベータやタウ蛋白などのバイオマーカーが開発されています。これらのバイオマーカーはアルツハイマー病の早期発見に有望であり、より早期の介入や治療を可能にします。さらに、機能的磁気共鳴画像法（fMRI）や陽電子放射断層撮影法（PET）などの神経画像診断技術の進歩により、アルツハイマー病の診断精度が向上しています。

アルツハイマー病の革新的な診断技術の最近の動向としては、p-tau217テストのような血液ベースのバイオマーカーの開発が挙げられます。もう一つの例は、認知機能評価やウェアラブルデバイスなどのデジタルバイオマーカーを使用して認知機能の低下を追跡し、アルツハイマー病の初期徴候を特定することです。バイオジェン社やエーザイ社などの企業も、臨床試験をサポートし、患者の転帰を改善するためにデジタルヘルス技術に投資しています。さらに、研究者は、発話パターンを分析し、認知機能低下の初期兆候を特定するための機械学習と自然言語処理の可能性を模索しています。こうした診断技術の進歩は、アルツハイマー病診断の分野に革命をもたらし、早期介入とより効果的な治療戦略を可能にすると期待されています。

整形外科疾患の負担を軽減することを目的とした、様々な臨床試験に資金を提供する政府資金援助プログラムの存在は、市場にプラスの影響を与えると予想されます。この資金は、高度な画像診断技術、バイオマーカーアッセイ、認知機能評価ツールなどの新しい診断技術の開発を支援しています。研究開発投資の増加は、技術革新のペースを加速させ、新しい診断ソリューションを市場に投入するのに役立ちます。

同市場における主要企業には、Quest Diagnostics、Labcorp、C2N Diagnostics、富士レビオ、Bristol Myers Squibb、Hoffmann-La Roche、Quanterixなどがあります。これらの企業は、世界な顧客に対応するため、製品の発売や承認など様々な戦略的取り組みを行っています。例えば、2024年4月、Quest Diagnostics社は、リン酸化タウ217（p-tau217）の新しい血液バイオマーカー検査を追加することにより、ポートフォリオの拡大を発表しました。各社はさらに、様々な血液ベースのバイオマーカー、脳脊髄液検査、遺伝学的検査に革新をもたらし、脳の健康に関する包括的な製品を提供しています。

アルツハイマー病診断市場レポート・ハイライト

• 診断技術に基づくと、画像診断技術が2023年に最大の収益シェアを占めました。このような取り組みが市場成長を牽引すると期待されます。この高いシェアは、疾患の早期かつ正確な発見が急務であることに起因します。コンピュータ断層撮影法（CT）、陽電子放射断層撮影法（PET）、機能的MRI（fMRI）などの画像技術の進歩は、疾患の診断とモニタリングのための重要なツールとして浮上しています。
• タイプ別では、診断が市場を独占し、2023年に最大のシェアを占めました。高齢化社会の進展に伴い、アルツハイマー病を発症するリスクのある人が増加し、世界市場は拡大しています。このため、早期かつ正確な診断ツールに対する需要が高まっており、市場を牽引しています。
• 最終用途別では、学術・研究機関が2023年に最大の市場シェアを占めました。これは、過去10年間における神経疾患の調査研究や臨床試験の増加に起因しています。学術・研究機関は、先端研究、臨床試験、革新的診断技術の開発の最前線にいます。
• 北米は、脳脊髄液分析および血液ベースのバイオマーカーを含むアルツハイマー病バイオマーカー研究の最前線にいる多数の主要な市場プレイヤーの存在により、世界市場を独占しています。これらの進歩は、より正確で低侵襲な診断検査の開発を促進しています。
• アジア太平洋地域は、2024年から2030年の予測期間において最も速い成長が見込まれています。これは、革新的な機器製造能力を持つメーカーの存在と診断研究の加速によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 アルツハイマー病診断市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/附随市場見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• アルツハイマー病診断市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 アルツハイマー病診断市場：診断技術別推定・動向分析

• セグメントダッシュボード
• アルツハイマー病診断市場：診断技術変動分析
• アルツハイマー病診断市場規模と動向分析、診断技術別、2018～2030年
• バイオマーカー
• イメージング技術
• 遺伝子検査
• 認知評価テスト

第5章 アルツハイマー病診断市場：タイプ別推定・動向分析

• タイプ別市場シェア、2023年と2030年
• セグメントダッシュボード
• 世界のアルツハイマー病診断市場の展望：タイプ別
• 2018年から2030年までの市場規模と予測および動向分析
• トリアージ
• 診断
• ふるい分け

第6章 アルツハイマー病診断市場：最終用途別推定・動向分析

• 最終用途市場シェア、2023年および2030年
• セグメントダッシュボード
• 世界のアルツハイマー病診断市場の展望：最終用途別
• 2018年から2030年までの市場規模と予測および動向分析
• 病院
• 診断ラボ
• 学術研究機関

第7章 アルツハイマー病診断市場：地域別推定・動向分析

• 地域別市場シェア分析、2023年および2030年
• 地域市場ダッシュボード
• 世界地域市場スナップショット
• 市場規模、予測動向分析、2018年から2030年：
• 北米
  • 北米： SWOT分析
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 欧州：SWOT分析
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋地域
  • アジア太平洋：SWOT分析
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ラテンアメリカ： SWOT分析
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカ：SWOT分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要ディストリビューターおよびチャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2023年
  • Quest Diagnostics Incorporated
  • Laboratory Corporation of America Holdings
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthineers AG
  • C2N diagnostics
  • FujireBio
  • Bristol Myers Squibb Company
  • Quanterix
  • Sysmex
  • Lantheus

List of Tables

• Table 1 List of abbreviations
• Table 2 North America Alzheimer's disease diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 3 North America Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 4 North America Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 5 North America Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 6 U.S. Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 7 U.S. Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 8 U.S. Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 9 Canada Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 10 Canada Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 11 Canada Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 12 Mexico Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 13 Mexico Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 14 Mexico Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 15 Europe Alzheimer's disease diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 16 Europe Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 17 Europe Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 18 Europe Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 19 Germany Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 20 Germany Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 21 Germany Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 22 UK Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 23 UK Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 24 UK Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 25 France Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 26 France Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 27 France Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 28 Italy Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 29 Italy Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 30 Italy Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 31 Spain Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 32 Spain Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 33 Spain Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 34 Denmark Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 35 Denmark Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 36 Denmark Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 37 Sweden Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 38 Sweden Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 39 Sweden Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 40 Norway Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 41 Norway Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 42 Norway Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific Alzheimer's disease diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 45 Asia Pacific Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 47 China Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 48 China Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 49 China Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 50 Japan Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 51 Japan Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 52 Japan Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 53 India Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 54 India Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 55 India Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 56 South Korea Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 57 South Korea Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 58 South Korea Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 59 Australia Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 60 Australia Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 61 Australia Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 62 Thailand Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 63 Thailand Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 64 Thailand Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 65 Latin America Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 66 Latin America Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 67 Latin America Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 68 Brazil Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 69 Brazil Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 70 Brazil Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 71 Argentina Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 72 Argentina Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 73 Argentina Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 74 MEA Alzheimer's disease diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 75 MEA Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 76 MEA Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 77 MEA Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 78 South Africa Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 79 South Africa Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 80 South Africa Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 81 Saudi Arabia Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 84 UAE Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 85 UAE Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 86 UAE Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 87 Kuwait Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
• Table 88 Kuwait Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Alzheimer's disease diagnostics market: market outlook
• Fig. 14 Alzheimer's disease diagnostics competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Penetration and growth prospect mapping
• Fig. 18 Industry value chain analysis
• Fig. 19 Alzheimer's disease diagnostics market driver impact
• Fig. 20 Alzheimer's disease diagnostics market restraint impact
• Fig. 21 Alzheimer's disease diagnostics market strategic initiatives analysis
• Fig. 22 Alzheimer's disease diagnostics market: Diagnostics technique movement analysis
• Fig. 23 Alzheimer's disease diagnostics market: Diagnostics technique outlook and key takeaways
• Fig. 24 Biomarkers market estimates and forecast, 2018 - 2030
• Fig. 25 CSF biomarkers estimates and forecast, 2018 - 2030
• Fig. 26 Blood based biomarkers market estimates and forecast, 2018 - 2030
• Fig. 27 Imaging techniques estimates and forecast, 2018 - 2030
• Fig. 28 Genetic testing market estimates and forecast, 2018 - 2030
• Fig. 29 Cognitive assessment tests market estimates and forecasts,2018 - 2030
• Fig. 30 Alzheimer's disease diagnostics Market: Test type movement analysis
• Fig. 31 Alzheimer's disease diagnostics market: Test type outlook and key takeaways
• Fig. 32 Triage market estimates and forecasts, 2018 - 2030
• Fig. 33 Diagnosis market estimates and forecasts,2018 - 2030
• Fig. 34 Screening market estimates and forecasts,2018 - 2030
• Fig. 35 Alzheimer's disease diagnostics market: End-use movement analysis
• Fig. 36 Alzheimer's disease diagnostics market: End-use outlook and key takeaways
• Fig. 37 Hospitals market estimates and forecasts, 2018 - 2030
• Fig. 38 Diagnostic laboratories market estimates and forecasts,2018 - 2030
• Fig. 39 Academic and research institutes market estimates and forecasts, 2018 - 2030
• Fig. 40 Global Alzheimer's disease diagnostics market: Regional movement analysis
• Fig. 41 Global Alzheimer's disease diagnostics market: Regional outlook and key takeaways
• Fig. 42 Global Alzheimer's disease diagnostics market share and leading players
• Fig. 43 North America market share and leading players
• Fig. 44 Europe market share and leading players
• Fig. 45 Asia Pacific market share and leading players
• Fig. 46 Latin America market share and leading players
• Fig. 47 Middle East & Africa market share and leading players
• Fig. 48 North America: SWOT
• Fig. 49 Europe SWOT
• Fig. 50 Asia Pacific SWOT
• Fig. 51 Latin America SWOT
• Fig. 52 MEA SWOT
• Fig. 53 North America, by country
• Fig. 54 North America
• Fig. 55 North America market estimates and forecasts, 2018 - 2030
• Fig. 56 U.S.
• Fig. 57 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 58 Canada
• Fig. 59 Canada market estimates and forecasts, 2018 - 2030
• Fig. 60 Mexico
• Fig. 61 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 62 Europe
• Fig. 63 Europe market estimates and forecasts, 2018 - 2030
• Fig. 64 UK
• Fig. 65 UK market estimates and forecasts, 2018 - 2030
• Fig. 66 Germany
• Fig. 67 Germany market estimates and forecasts, 2018 - 2030
• Fig. 68 France
• Fig. 69 France market estimates and forecasts, 2018 - 2030
• Fig. 70 Italy
• Fig. 71 Italy market estimates and forecasts, 2018 - 2030
• Fig. 72 Spain
• Fig. 73 Spain market estimates and forecasts, 2018 - 2030
• Fig. 74 Denmark
• Fig. 75 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 76 Sweden
• Fig. 77 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 78 Norway
• Fig. 79 Norway market estimates and forecasts, 2018 - 2030
• Fig. 80 Asia Pacific
• Fig. 81 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 82 China
• Fig. 83 China market estimates and forecasts, 2018 - 2030
• Fig. 84 Japan
• Fig. 85 Japan market estimates and forecasts, 2018 - 2030
• Fig. 86 India
• Fig. 87 India market estimates and forecasts, 2018 - 2030
• Fig. 88 Thailand
• Fig. 89 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 90 South Korea
• Fig. 91 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 92 Australia
• Fig. 93 Australia market estimates and forecasts, 2018 - 2030
• Fig. 94 Latin America
• Fig. 95 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 96 Brazil
• Fig. 97 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 98 Argentina
• Fig. 99 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 100 Middle East and Africa
• Fig. 101 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 102 South Africa
• Fig. 103 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 104 Saudi Arabia
• Fig. 105 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 106 UAE
• Fig. 107 UAE market estimates and forecasts, 2018 - 2030
• Fig. 108 Kuwait
• Fig. 109 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 110 Market share of key market players- Alzheimer's disease diagnostics market

Alzheimer's Disease Diagnostics Market Growth & Trends:

The global Alzheimer's disease diagnostics market size is expected to reach USD 15.92 billion by 2030, registering a CAGR of 11.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by rising prevalence of Alzheimer's disease (AD), growing use of biomarkers in disease diagnostics, growing adoption of personalized products, and increasing technological advancements in medical imaging are some of the factors which is expected to drive the demand for Alzheimer's disease diagnostics. Increasing government investments and R&D studies is further propelling growth.

The global aging population with chronic conditions such as Alzheimer's disease, which is the most common form of dementia, is another major factor driving the market for Alzheimer's disease diagnostics. According to the WHO, Alzheimer's disease causes 60-70% of all instances of dementia, making it the most common kind. According to the Alzheimer's Association reports, an estimated 6.7 million Americans aged 65 and older were living with Alzheimer's disease in 2023. This number is projected to nearly triple to 13.8 million people by 2060, and the studies project that the healthcare cost for AD patients in 2022 was around USD 321 billion in the U.S, itself.

The market trends are shifting towards the development of more accurate and non-invasive diagnostic tools. Recent advances in technology have led to the development of biomarkers, such as amyloid-beta and tau proteins, which can be detected in cerebrospinal fluid or blood samples. These biomarkers have shown promise in detecting Alzheimer's disease in its early stages, allowing for earlier intervention and treatment. Additionally, advances in neuroimaging techniques, such as functional magnetic resonance imaging (fMRI) and positron emission tomography (PET), have improved the accuracy of Alzheimer's disease diagnosis.

Recent examples of innovative diagnostic technologies for Alzheimer's disease include the development of blood-based biomarkers, such as the p-tau217 test, which has shown high accuracy in detecting the disease. Another example is the use of digital biomarkers, such as cognitive assessments and wearable devices, to track cognitive decline and identify early signs of Alzheimer's disease. Companies such as Biogen and Eisai are also investing in digital health technologies to support clinical trials and improve patient outcomes. Moreover, researchers are exploring the potential of machine learning and natural language processing to analyze speech patterns and identify early signs of cognitive decline. These advances in diagnostic technology are expected to revolutionize the field of Alzheimer's disease diagnosis, enabling earlier intervention and more effective treatment strategies.

Presence of government funding programs aimed at reducing the burden of orthopedic diseases, by funding various clinical trials aimed at, is expected to have a positive impact on the market, In addition, governments are allocating substantial funds for research and development (R&D) in the field of Alzheimer's diagnostics. This funding supports the development of new diagnostic technologies, such as advanced imaging techniques, biomarker assays, and cognitive assessment tools. Increased R&D investment accelerates the pace of innovation and helps bring new diagnostic solutions to the market

Some of the key players in the market are Quest Diagnostics, Labcorp, C2N Diagnostics, Fujirebio, Bristol Myers Squibb, Hoffmann-La Roche, and Quanterix. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in April 2024, Quest Diagnostics announced its portfolio expansion by adding a new blood biomarker test for phosphorylated tau 217 (p-tau217). Companies further have been innovating in various blood-based biomarkers, cerebrospinal fluid tests, and genetic tests to provide a comprehensive offering in brain health.

Alzheimer's Disease Diagnostics Market Report Highlights:

• Based on diagnostics technique, imaging techniques accounted for the largest revenue share in 2023. Such initiatives are expected to drive market growth. This high share is attributable to the urgent need for early and accurate detection of the disease. Advancements in imaging technologies such as Computed Tomography (CT), Positron Emission Tomography (PET), functional MRI (fMRI) have emerged as crucial tools for diagnosing and monitoring the disease.
• Based on type, diagnosis dominated the market and accounted for the largest share in 2023. The global market is expanding as the aging population rises, with more individuals at risk of developing Alzheimer's disease. This has heightened the demand for early and accurate diagnostic tools, driving the market forward.
• Based on end use, academic and research institutes segment dominated the market with the largest market share in 2023. This is attributable to the increase in the research studies and clinical trials for neurological disorders over the last decade. Academic and research institutes are at the forefront of advanced research, clinical trials, and the development of innovative diagnostic techniques.
• North America dominated the global market due to the presence of a large number of major market players at the forefront of research into Alzheimer's disease biomarkers, including cerebrospinal fluid analysis and blood-based biomarkers. These advancements are driving the development of more accurate and minimally invasive diagnostic tests.
• Asia Pacific region is expected to witness the fastest growth over the forecast period from 2024 to 2030, due to presence of manufacturers with innovative devices manufacturing capabilities coupled with accelerated diagnostic research capabilities.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Diagnostics Technique
  • 1.2.2. Type
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Diagnostics Technique outlook
  • 2.2.2. Type outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Alzheimer's Disease Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of Alzheimer's disease
    • 3.2.1.2. Increasing use of biomarkers in diagnosis
    • 3.2.1.3. Growing adoption of personalized products
    • 3.2.1.4. Growing R&D studies and government investments
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Stringent regulations
• 3.3. Alzheimer's Disease Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
  • 3.3.2. PESTEL Analysis

Chapter 4. Alzheimer's Disease Diagnostics Market: Diagnostics Technique Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Alzheimer's Disease Diagnostics Market: Diagnostics Technique Movement Analysis
• 4.3. Alzheimer's Disease Diagnostics Market Size & Trend Analysis, by diagnostic technique, 2018 to 2030 (USD Million)
• 4.4. Biomarker
  • 4.4.1. Biomarker Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. CSF Biomarkers
    • 4.4.2.1. CSF Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Blood Based Biomarker
    • 4.4.3.1. Blood Based Biomarker Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Imaging Techniques
  • 4.5.1. Imaging Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Genetic Testing
  • 4.6.1. Genetic Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Cognitive Assessment Tests
  • 4.7.1. Cognitive Assessment Tests Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Alzheimer's Disease Diagnostics Market: Type Estimates & Trend Analysis

• 5.1. Type Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Alzheimer's Disease Diagnostics Market by Type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Triage
  • 5.5.1. Triage Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Diagnosis
  • 5.6.1. Diagnosis Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Screening
  • 5.7.1. Screening Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Alzheimer's Disease Diagnostics Market: End Use Estimates & Trend Analysis

• 6.1. End Use Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Alzheimer's Disease Diagnostics Market by End Use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Hospitals
  • 6.5.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Diagnostic Laboratories
  • 6.6.1. Diagnostic Laboratories Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Academic and Research Institutes
  • 6.7.1. Academic and Research Institutes Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Alzheimer's Disease Diagnostics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. North America: SWOT Analysis
  • 7.5.2. U.S.
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/Reimbursement
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/Reimbursement
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/Reimbursement
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. Europe: SWOT Analysis
  • 7.6.2. UK
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/Reimbursement
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. Germany
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/Reimbursement
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. France
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/Reimbursement
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Italy
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/Reimbursement
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Spain
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/Reimbursement
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Norway
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/Reimbursement
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Sweden
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/Reimbursement
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.9. Denmark
    • 7.6.9.1. Key country dynamics
    • 7.6.9.2. Regulatory framework/Reimbursement
    • 7.6.9.3. Competitive scenario
    • 7.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Asia Pacific: SWOT Analysis
  • 7.7.2. Japan
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/Reimbursement
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. China
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/Reimbursement
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. India
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/Reimbursement
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. Australia
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/Reimbursement
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. South Korea
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/Reimbursement
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.7. Thailand
    • 7.7.7.1. Key country dynamics
    • 7.7.7.2. Regulatory framework/Reimbursement
    • 7.7.7.3. Competitive scenario
    • 7.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Latin America: SWOT Analysis
  • 7.8.2. Brazil
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/Reimbursement
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework/Reimbursement
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. MEA: SWOT Analysis
  • 7.9.2. South Africa
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/Reimbursement
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. Saudi Arabia
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/Reimbursement
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. UAE
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/Reimbursement
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.5. Kuwait
    • 7.9.5.1. Key country dynamics
    • 7.9.5.2. Regulatory framework
    • 7.9.5.3. Competitive scenario
    • 7.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Quest Diagnostics Incorporated
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Services benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Laboratory Corporation of America Holdings
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Services benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. F. Hoffmann-La Roche Ltd.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Services benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Siemens Healthineers AG
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Services benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. C2N diagnostics
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Services benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. FujireBio
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Services benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Bristol Myers Squibb Company
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Services benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Quanterix
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Services benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Sysmex
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Services benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Lantheus
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Services benchmarking
    • 8.3.13.4. Strategic initiatives